{"entity":{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","aka":[],"tldr":"Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.","summary":"Kyowa Kirin, based in Tokyo, listed as 4151.T and part of the Kirin group, is a Japanese biopharmaceutical company whose oncology products include mogamulizumab, sold as Poteligeo, for cutaneous T-cell lymphoma and toremifene, sold as Fareston, for metastatic breast cancer. It developed the anti-CCR4 antibody mogamulizumab, markets Fareston in the United States, and also sells burosumab as Crysvita and G-CSF products in Japan. OnCo links it to the toremifene drug record. Whether a CCR4 antibody can find uses beyond rare T-cell lymphomas is the open question for its oncology franchise. Toremifene has its own page. On 13 November 2025 the FDA approved ziftomenib, sold as Komzifti, for adults with relapsed or refractory acute myeloid leukaemia with a susceptible NPM1 mutation; Kyowa Kirin co-develops it with Kura Oncology, leading strategy outside the United States and sharing some US commercial work.","asOf":"2026-10-29","wikipedia":"https://en.wikipedia.org/wiki/Kyowa_Kirin","links":[{"label":"Official website","url":"https://www.kyowakirin.com"},{"label":"Kura Oncology 8-K on the Komzifti approval (13 November 2025)","url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525280255/d159173d8k.htm"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab","toremifene","burosumab","ziftomenib"],"companies":["kura-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629726","nct07623616","komet-001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Checked 29 October 2026 against Kura Oncology's SEC 8-K for the ziftomenib approval; no acquisition or exit from oncology by Kyowa Kirin was found in 2025 or 2026. The Kyowa Kirin newsroom list did not load for this check."],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.kyowakirin.com","ticker":"4151.T","investors":[],"funding":[]},"route":"/companies/kyowa-kirin/","neighbours":{"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"drug":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/"},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/"}],"company":[{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/"},{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/"}],"trial":[{"id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/"},{"id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/"},{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/"}],"paper":[{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/"}]}}